Mission and vision
Since its inception the CTS mission and vision remain the same, to stimulate the momentum of the medical devices sector and actively participate in Quebec’s regional development dynamics in the areas of healthcare technologies.
Its mission is to ensure the development and sustainable growth of promising enterprises in the medical technologies sector and to enhance their national and international exposure.
The CTS mission is to provide a unique value proposition for the start-up with a professional framework that allows them to be focus on their technology development, to raise the market dynamics and to receive the international visibility that they need to start and to expand.
The CTS acts as a springboard for medical device founders to accelerate the transition of their business from early technical and prototyping validations to the initial market penetration.
The CTS is focused on three very specific goals :
- Validation to confirm that enough potential customers will be interested in the product and/or service, and make modifications to the solution as necessary.
- Customer Creation to focus the enterprise on building a demand for their product and/or services and to improve the efficiency of the customer acquisition process.
- Initial Scaling to show clear, growing and measurable user/market traction in target market(s) that can be sustained.
Unique value proposition
CTS offers medical technology start-ups a very unique value proposition, that allows promising start-ups to focus on early market penetration, and initiate market traction, bypassing the common struggle of founder’s to bootstrap technologies into products. The CTS comprehensive, two-year support program covers all aspects of building a medical device company including financing, market penetration, mentoring.
Selecting candidate Start-ups
Companies applying to the CTS will have to demonstrate that they are headquartered in Quebec, with the objective to remained so and that have built a unique minimum viable product past the prototyping stage for the CTS to support their regulatory strategy in order to initiate commercialization through niche sales channels targeting early adopters and key opinion leaders. Relevant candidate companies are those where the CTS determines that such objectives could be achieved with the level of funding offered by the CTS during a 24 month period.
Compagnies after the CTS program
Companies exiting CTS will be prepared to continue scaling and have demonstrated the traction necessary to access subsequent levels of funding to drive growth aggressively, while continuing to benefit from the network offered to CTS alumni.
Accomplished business executive, expert intrapreneur, author, and mentor.
Business leader with over 25 years in management and leadership in the life sciences industry.
Commited to support the development of medical technologies in Canada.
Industrial Technology Advisor IRAP the National Research Council of Canada.
Associate Vice President, Technology investments at Desjardins Venture Capital
Director of R&D, Medical Devices at National Research Council Canada
Student of a bachelor's degree in communication (human relations) and holds a diploma in business management.
Partner, Intellectual Property Group at Fasken Martineau DuMoulin.
Senior Director Marketing and Strategy - TELUS Health.
Director - Strategic Investments and relations with sponsors
Sr Dir. Legal, Scientific Affairs and Business Dev. at Medtronic of Canada.
Co-founder, VP R&D and Regulatory Affairs of Cadens Medical Imaging.
Partner at PwC, Head of Transactions Group and of the Business Acquisitions Group in Quebec.
Vice-president of medical robotics at Kinova.
President and CEO at Thorasys inc.